32953 Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years

Abstract

Introduction: VOYAGE-1&2 phase 3 studies evaluated efficacy and safety of guselkumab (GUS) in patients with moderate-to-severe plaque psoriasis. Five-year efficacy was examined by baseline disease characteristics and treatment history.